Biomea Fusion Inc
NASDAQ:BMEA
Biomea Fusion Inc
Total Liabilities
Biomea Fusion Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomea Fusion Inc
NASDAQ:BMEA
|
Total Liabilities
$28.4m
|
CAGR 3-Years
60%
|
CAGR 5-Years
148%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$136.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$37.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$81.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
Biomea Fusion Inc
Glance View
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.
See Also
What is Biomea Fusion Inc's Total Liabilities?
Total Liabilities
28.4m
USD
Based on the financial report for Dec 31, 2024, Biomea Fusion Inc's Total Liabilities amounts to 28.4m USD.
What is Biomea Fusion Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
148%
Over the last year, the Total Liabilities growth was -8%. The average annual Total Liabilities growth rates for Biomea Fusion Inc have been 60% over the past three years , 148% over the past five years .
